Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
Authors
Keywords
-
Journal
INFECTION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-02
DOI
10.1007/s15010-020-01520-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
- (2020) Ryan K. Shields ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Comparison of Treatment Outcomes Between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients With Imipenem-Nonsusceptible Bacterial Infections
- (2020) Keith S. Kaye et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome
- (2020) Iain J. Abbott et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii
- (2020) V. Aranzana-Climent et al. CLINICAL MICROBIOLOGY AND INFECTION
- Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria
- (2020) Diamantis P. Kofteridis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
- (2020) Irene Galani et al. Eurosurveillance
- Evaluation of Eravacycline: A Novel Fluorocycline
- (2020) Sara Alosaimy et al. PHARMACOTHERAPY
- Early Experience with Eravacycline for Complicated Infections
- (2020) S Alosaimy et al. Open Forum Infectious Diseases
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Re: ‘Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes’ by Nutman et al.
- (2020) S. Karakonstantis CLINICAL MICROBIOLOGY AND INFECTION
- Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
- (2020) Amir Nutman et al. CLINICAL MICROBIOLOGY AND INFECTION
- Intrathecal Antibacterial and Antifungal Therapies
- (2020) Roland Nau et al. CLINICAL MICROBIOLOGY REVIEWS
- Ceftazidime-Avibactam Activity against a Challenge Set of Carbapenem-Resistant Enterobacterales: Ompk36 L3 Alterations and β-Lactamases with Ceftazidime Hydrolytic Activity Lead to Elevated MIC Values
- (2020) Mariana Castanheira et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model
- (2020) Iain J Abbott et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance
- (2020) Paolo Gaibani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa
- (2020) Gabriel T Cuba et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece
- (2020) Irene Galani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
- (2020) Thomas P Lodise et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae
- (2020) Buket Erturk Sengel et al. JOURNAL OF CHEMOTHERAPY
- Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-β-Lactamase-Producing Pseudomonas aeruginosa
- (2020) Christian M. Gill et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps from Metallo-β-Lactamase Negative Klebsiella pneumoniae.
- (2020) Punyawee Dulyayangkul et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis
- (2020) Yuan-yuan Li et al. BMC INFECTIOUS DISEASES
- Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications
- (2020) Stamatis Karakonstantis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii
- (2020) Stamatis Karakonstantis JOURNAL OF CHEMOTHERAPY
- In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii
- (2020) Carlos Hernán Rodriguez et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
- (2020) Marco Fiore et al. Antibiotics-Basel
- Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
- (2020) Naoki Kohira et al. Journal of Global Antimicrobial Resistance
- Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae
- (2019) William R. Wilson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens
- (2019) Ilias Karaiskos et al. Expert Opinion on Drug Metabolism & Toxicology
- Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
- (2019) Melissa D. Barnes et al. mBio
- Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
- (2019) James A. McKinnell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and role of PK/PD in dose optimization
- (2019) Sazlyna Mohd Sazlly Lim et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in Intensive Care Units in Spain: The SUPERIOR multicentre study
- (2019) Sergio García-Fernández et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Carbapenem-resistant Acinetobacterbaumannii: in pursuitof an effective treatment
- (2019) Evangelia-Theophano Piperaki et al. CLINICAL MICROBIOLOGY AND INFECTION
- Comparison of five methods for detection of carbapenemases in Enterobacterales with proposal of a new algorithm
- (2019) Luis Lucena Baeza et al. CLINICAL MICROBIOLOGY AND INFECTION
- Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial
- (2019) Keith S Kaye et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
- (2019) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
- (2019) Shampa Das et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Aztreonam plus clavulanate, tazobactam or avibactam for the treatment of metallo-β-lactamase-producing-Gram negative related infections
- (2019) Cécile Emeraud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis
- (2019) Matteo Bassetti et al. ADVANCES IN THERAPY
- Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis
- (2019) Xingran Du et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii
- (2019) Sutep Jaruratanasirikul et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam
- (2019) Matthaios Papadimitriou-Olivgeris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents
- (2019) Tomefa E Asempa et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa
- (2019) Lindsay M. Avery et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Molecular mechanisms related to colistin resistance in Enterobacteriaceae
- (2019) Zahra Aghapour et al. Infection and Drug Resistance
- Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae
- (2019) Matthew C. Canver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
- (2019) Sandra Mikhail et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
- (2019) Katherine Young et al. BMC MICROBIOLOGY
- Antibiotic resistance in Pseudomonas aeruginosa – mechanisms, epidemiology and evolution
- (2019) João Botelho et al. DRUG RESISTANCE UPDATES
- Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection
- (2019) Victor I. Band et al. Nature Microbiology
- The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence
- (2019) Paraskevi Fragkou et al. Microorganisms
- Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity
- (2019) Linda Mueller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis
- (2019) Massimo Mentasti et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- The epidemiology and characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in a large intensive care unit in Jakarta, Indonesia
- (2019) Yulia Rosa Saharman et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- EFFICACY OF CEFTAZIDIME-AVIBACTAM IN MONOTHERAPY OR COMBINATION THERAPY AGAINST CARBAPENEM RESISTANT GRAM NEGATIVE ORGANISMS: A META-ANALYSIS
- (2019) Lorenzo Onorato et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007–16 study
- (2019) Melissa G McCracken et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Systematic comparison of four methods for the detection of carbapenemase-producing Enterobacterales (CPE) directly from blood cultures
- (2019) Maria Meier et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials
- (2019) Simone Lanini et al. LANCET INFECTIOUS DISEASES
- In Vitro Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Clinical Isolates of Meropenem-Non-Susceptible Pseudomonas aeruginosa: A Two-Center Study
- (2019) Hasan Cenk Mirza et al. Journal of Global Antimicrobial Resistance
- Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants
- (2019) Pablo Fraile-Ribot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options
- (2019) Stamatis Karakonstantis et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Extensive drug resistant Acinetobacter baumannii: a comparative study between non-colistin based combinations
- (2019) Eman Elsayed et al. International Journal of Clinical Pharmacy
- Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation
- (2019) Xiangqing Song et al. Frontiers in Microbiology
- Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
- (2019) Matteo Bassetti et al. Infection and Drug Resistance
- 610. Meropenem-vaborbactam (MV) In Vitro Activity Against Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Isolates with Outer Membrane Porin Gene Mutations
- (2019) Mohamad Yasmin et al. Open Forum Infectious Diseases
- Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii
- (2019) Mohammad Hamidian et al. Microbial Genomics
- In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase–4 and New Delhi Metallo-β-Lactamase–1
- (2019) Mohamad Yasmin et al. CLINICAL INFECTIOUS DISEASES
- Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
- (2019) Shampa Das et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii
- (2019) Harald Seifert et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections
- (2019) Iain J Abbott et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model
- (2018) Arnold Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations
- (2018) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae
- (2018) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals
- (2018) L. Papst et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015
- (2018) George G. Zhanel et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
- (2018) Michael A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii
- (2018) Harald Seifert et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- MALDI-TOF for the rapid detection of carbapenemase-producing Enterobacteriaceae: comparison of the commercialized MBT STAR®-Carba IVD Kit with two in-house MALDI-TOF techniques and the RAPIDEC® CARBA NP
- (2018) Laurent Dortet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme
- (2018) James A Karlowsky et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15
- (2018) Krystyna M Kazmierczak et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics
- (2018) Craig R. MacNair et al. Nature Communications
- Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae
- (2018) Thea Brennan-Krohn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program, 2012 to 2015
- (2018) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016
- (2018) Irene Galani et al. Eurosurveillance
- Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences
- (2018) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms
- (2018) Mariana Castanheira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
- (2018) Pranita D. Tamma et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review
- (2018) Amelia Pietropaolo et al. Current Urology Reports
- Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
- (2018) Mariadelfina Molinaro et al. Infection and Drug Resistance
- Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
- (2018) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017
- (2018) Carl Suetens et al. Eurosurveillance
- Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin
- (2018) Garyfallia Poulakou et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Minocycline susceptibility breakpoints for Acinetobacter baumannii: do we need to re-evaluate them?
- (2018) Athanasios Tsakris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan
- (2018) Shun-Chung Hsueh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molecular Epidemiology of Endemic Carbapenem-Resistant Gram-Negative Bacteria in an Intensive Care Unit
- (2018) Theodoros Karampatakis et al. Microbial Drug Resistance
- Colistin Monotherapy Versus Colistin and Rifampin Combination Therapy in Pneumonia Caused by Colistin-resistant Acinetobacter baumannii: A Randomized Controlled Trial
- (2018) Hye Jung Park et al. Journal of Global Antimicrobial Resistance
- Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study
- (2018) Ayelet Raz-Pasteur et al. Journal of Global Antimicrobial Resistance
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae
- (2017) M. Souli et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000–2015)
- (2017) Theodoros Karampatakis et al. Future Microbiology
- Predominance of international clone 2 OXA-23-producing- Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study
- (2017) Spyros Pournaras et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Revival of old antibiotics: needs, the state of evidence and expectations
- (2017) Hiba Zayyad et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model
- (2017) Céline Pouzot-Nevoret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae
- (2017) Aurélie Jayol et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
- (2017) Evelyn Shaw et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity
- (2017) Justin R. Lenhard et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases
- (2017) Shazad Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
- (2017) Senthil Natesan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates
- (2017) Valérie Denervaud-Tendon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis
- (2017) Haojun Chen et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
- (2017) Belén Gutiérrez-Gutiérrez et al. LANCET INFECTIOUS DISEASES
- Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
- (2017) Hajo Grundmann et al. LANCET INFECTIOUS DISEASES
- Alterations in Outer Membrane Permeability Favor Drug-Resistant Phenotype of Klebsiella pneumoniae
- (2017) Lucia Pulzova et al. Microbial Drug Resistance
- Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram–Negative Organisms?
- (2017) Chaitra Shankar et al. Microbial Drug Resistance
- In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis
- (2017) Jian Li et al. Microbial Drug Resistance
- In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital
- (2017) Yongyut Lertsrisatit et al. Infection and Drug Resistance
- In VitroBactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates
- (2016) Martha Nepka et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSynergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii
- (2016) Seongman Bae et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused byAcinetobacterbaumannii
- (2016) Sutep Jaruratanasirikul et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
- (2016) Alexandre P. Zavascki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
- (2016) Darren Wong et al. CLINICAL MICROBIOLOGY REVIEWS
- Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance
- (2016) Spyros Pournaras et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii
- (2016) Sibylle H. Lob et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation
- (2016) O. Asuphon et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study
- (2016) Alexandre Brasseur et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae
- (2016) Ritu Banerjee et al. Virulence
- The global epidemiology of carbapenemase-producing Enterobacteriaceae
- (2016) David van Duin et al. Virulence
- Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms
- (2016) Gleice Cristina Leite et al. PLoS One
- In VitroActivity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations
- (2015) Hervé Dupont et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam
- (2015) Jean-Marie Pagès et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on theIn VitroActivity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae
- (2015) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
- (2015) Zubair A. Qureshi et al. CLINICAL INFECTIOUS DISEASES
- Polymyxin B versus colistin: an update
- (2015) Yiying Cai et al. Expert Review of Anti-Infective Therapy
- Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence
- (2015) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
- (2015) Raymond Testa et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen
- (2015) Alessandra Oliva et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Activity of ceftazidime/avibactam against isogenic strains ofEscherichia colicontaining KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop
- (2015) Marisa L. Winkler et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitropharmacodynamics of fosfomycin against clinical isolates ofPseudomonas aeruginosa
- (2015) Clare C. Walsh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The β-Lactams Strike Back: Ceftazidime-Avibactam
- (2015) Evan J. Zasowski et al. PHARMACOTHERAPY
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals
- (2014) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
- (2014) Rujipas Sirijatuphat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
- (2014) R. L. Nation et al. CLINICAL INFECTIOUS DISEASES
- Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections
- (2014) A. Oliva et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
- (2014) M. Castanheira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
- (2013) Emanuele Durante-Mangoni et al. CLINICAL INFECTIOUS DISEASES
- Screening and deciphering antibiotic resistance inAcinetobacter baumannii: a state of the art
- (2013) Rémy A Bonnin et al. Expert Review of Anti-Infective Therapy
- Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature
- (2013) R. Giua et al. INFECTION
- Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria
- (2013) Konstantinos Pontikis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
- (2013) L Silvia Munoz-Price et al. LANCET INFECTIOUS DISEASES
- MALDI-TOF MS, a useful instrument for differentiating metallo-β-lactamases inEnterobacteriaceaeandPseudomonasspp.
- (2013) Y. Hoyos-Mallecot et al. LETTERS IN APPLIED MICROBIOLOGY
- In VitroSynergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
- (2012) Céline Vidaillac et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases
- (2012) M. Baroud et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies
- (2012) Y. Cai et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii
- (2011) Carlos Hernan Rodríguez et al. JOURNAL OF INFECTION
- Amikacin Monotherapy for Sepsis Caused by Panresistant Pseudomonas aeruginosa
- (2010) B. Layeux et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia
- (2010) Jeannie D. Chan et al. JOURNAL OF INTENSIVE CARE MEDICINE
- Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin
- (2009) Rodriguez Carlos Hernan et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK
- (2009) M. Doumith et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
- (2008) Helen W. Boucher et al. CLINICAL INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now